GlassScriptPhysician profile
Cheryl E Axelrod
NPI 1801069455
$1,859.62
in general payments reported to CMS, 2019-2025
28 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $82.24 · 2021: $58.38 · 2022: $71.34 · 2023: $365 · 2024: $478 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $204.21 | 2023-2025 | |
| Coopersurgical, INC. | $165.60 | 2019-2025 | Paragard T 380a, Paragard T 380a, Wallach Cryosurgical Equipment |
| Abbvie INC. | $157.26 | 2019-2024 | Lo Loestrin Fe |
| Astellas Pharma US INC | $144.38 | 2019-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $129.96 | 2019-2025 | |
| Medtronic, INC. | $114.16 | 2022-2024 | Truclear |
| Exeltis, USA INC. | $98.85 | 2024-2025 | Slynd |
| Therapeuticsmd, INC. | $94.96 | 2019-2020 | |
| Amgen INC. | $87.45 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $81.99 | 2025 | Myfembree |
| Organon LLC | $80.08 | 2023-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $69.27 | 2019-2023 | Gardasil 9 |
| Amag Pharmaceuticals, INC. | $55.93 | 2019 | |
| Pfizer INC. | $44.73 | 2023 | |
| Allergan, INC. | $44.55 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $34.73 | 2019 | |
| Hologic Sales and Service, LLC | $33.90 | 2019-2023 | Thinprep 2000 Processor, Aptima |
| Becton, Dickinson and Company | $31.93 | 2023 | Bd Onclarity |
| Dysis Medical, INC. | $31.23 | 2019-2020 | |
| Novo Nordisk INC | $25.92 | 2019 | |
| Exact Sciences Corporation | $24.92 | 2025 | Cologuard Collection Kit |
| Millicent US INC | $23.26 | 2024 | Femring, Intrarosa |
| Aspira Women'S Health INC | $20.16 | 2024 | Ova1 |
| Acessa Health INC. | $17.53 | 2019 | |
| Agile Therapeutics, INC. | $17.23 | 2024 | Twirla |
| Roche Diagnostics Corporation | $14.63 | 2019 | |
| Lupin INC. | $10.80 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Axelrod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.